Neurons generated from stem cells (from skin fibroblasts) of a patient with sporadic Alzheimer’s disease. Visualized with a specific green fluorescent marker. Nuclei are shown in blue. Researchers ...

Oral NMDA receptor antagonist gets an expanded indication ...

Researchers from the Institute for Neurosciences (IN), a joint center of the Miguel Hernández University of Elche (UMH) and the Spanish National Research Council (CSIC), who are also part of the ...

Axsome Therapeutics recently held a special call to discuss the past approval of AUVELITY, a therapy targeting NMDA and sigma-1 receptors, for treating agitation associated with dementia due to ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...

Axsome Therapeutics' Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's ...

FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...

Scientists have long been racking their brains to crack the mechanism behind Alzheimer’s disease progression. They may have finally found a crucial clue. A research team from Heidelberg University in ...

A molecular mechanism that significantly contributes to the progression of Alzheimer's disease has been discovered by a research team led by neurobiologist Prof. Dr. Hilmar Bading of Heidelberg ...

A molecular mechanism that significantly contributes to the progression of Alzheimer’s disease has been discovered by a research team led by neurobiologist Prof. Dr Hilmar Bading of Heidelberg ...

A variety of Alzheimer’s medications can help manage different symptoms and improve quality of life as the disease progresses. Alzheimer’s medications help manage symptoms by improving memory, ...